<DOC>
	<DOCNO>NCT00761514</DOCNO>
	<brief_summary>The primary objective study evaluate quality life change Puerto Rican subject Rheumatoid Arthritis treat Humira ( adalimumab ) first Anti-TNF Monoclonal Antibody .</brief_summary>
	<brief_title>Evaluation Quality Life Changes Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject voluntarily sign date informed consent form , approve Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) , prior studyspecific procedure . Subject 18 year age old . If female , subject either childbearing potential , defined postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , childbearing potential practice one follow method birth control : condom , sponge , foam , jelly , diaphragm intrauterine device ( IUD ) . contraceptive ( oral parenteral ) three month prior study drug administration ) . vasectomized partner . total abstinence sexual intercourse . If female , result serum pregnancy test perform Screening , prior first dose Humira ( adalimumab ) must negative . Subject confirm diagnosis active rheumatoid arthritis define &gt; = 6 swollen joint &gt; = 9 tender joint . Subject Erythrocyte Sedimentation Rate ( ESR ) &gt; 20 mm/hr . ESR measure use Westergren method . Subject meet American College Rheumatology ( ACR ) criteria diagnosis rheumatoid arthritis ( RA ) least 3 month prior enrollment require start biologic contain treatment first time , investigator chooses Humira ( adalimumab ) . Subject unsatisfactory response intolerance one prior diseasemodifying antirheumatic drug ( DMARDS ) ( e.g. , hydroxychloroquine , leflunomide , methotrexate , parenteral gold , sulfasalazine , azathioprine combination ) . Subject evaluation latent tuberculosis tuberculosis ( TB ) skin test do screen visit . Subjects evidence prior TB infection give prophylaxis accordance Centers Disease Control Prevention ( CDC ) guideline . Subjects prior treatment cyclophosphamide , chlorambucil Tumor Necrosis Factor ( TNF ) biologic etanercept , infliximab , anakinra , abatacept adalimumab . Subjects previously treat total lymphoid irradiation antiCD4 CAMPATH 1H monoclonal antibody result persistent CD4 lymphopenia ( CD4 lymphocytes &lt; = 500/mm3 ) . Subject prior treatment intravenous ( IV ) immunoglobulin investigational agent within 30 day screen visit . Subject history cancer within past 10 year resect basal cell squamous cell carcinoma skin . Subject history malignant lymphoma leukemia regardless time since diagnosis . Subject history current acute inflammatory joint disease origin RA , e.g. , Mixed Connective Tissue Disease ( MCTD ) , Systematic Lupus Erythematosus ( SLE ) , etc . Subject history uncontrolled diabetes mellitis , unstable ischemic heart disease , active inflammatory bowel disease , active peptic ulcer disease , recent cerebrovascular accident ( CVA ) ( within 3 month ) , opinion investigator , would put subject risk participation protocol . Subject history active tuberculosis listeriosis , active infection suggestive significant profound immunosuppression , Pneumocystis carinii , aspergillosis systemic protozoan fungal infection . Subject positive serology Hepatitis B Hepatitis C indicate active infection . Subject history positive HIV status define enzymelinked immunosorbent assay ( ELISA ) positive test confirm Western blot test and/or polymerase chain reaction ( PCR ) . Subject persistent severe infection ( ) require hospitalization treatment intravenous ( IV ) antibiotic within 30 day , oral antibiotic within 14 day , prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>